Clinuvel Pharmaceuticals Limited
CLVLY · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7.8% | 12.6% | 19.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 83.3% | 91.2% | 64.6% | 70.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 60.2% | 63.8% | 53.2% | 51.5% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 38.1% | 40.4% | 39.1% | 31.8% |
| EPS Diluted | 0.72 | 0.7 | 0.59 | 0.4 |
| % Growth | 2.9% | 18.6% | 47.5% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |